Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by SHI-MING TU and CHRISTOPHER J LOGOTHETIS.
SHI-MING TU
Connection Strength
5.645
CHRISTOPHER J LOGOTHETIS
  1. Application of a Successful Germ Cell Tumor Paradigm to the Challenges of Common Adult Solid Cancers. J Cell Sci Ther. 2021; 12(6).
    View in: PubMed
    Score: 0.759
  2. Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer. Clin Adv Hematol Oncol. 2010 May; 8(5):341-51.
    View in: PubMed
    Score: 0.362
  3. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol. 2009 Jul 10; 27(20):3319-24.
    View in: PubMed
    Score: 0.338
  4. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol. 2005 Nov 01; 23(31):7904-10.
    View in: PubMed
    Score: 0.265
  5. Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP). Urol Oncol. 2003 Sep-Oct; 21(5):342-8.
    View in: PubMed
    Score: 0.228
  6. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2003 Aug 06; 95(15):1174-5; author reply 1175.
    View in: PubMed
    Score: 0.227
  7. Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol. 2002 Aug; 3(8):508-13.
    View in: PubMed
    Score: 0.212
  8. Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer. 2002 May 15; 94(10):2610-7.
    View in: PubMed
    Score: 0.209
  9. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001 Feb 03; 357(9253):336-41.
    View in: PubMed
    Score: 0.191
  10. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Na?ve Metastatic Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):990-999.
    View in: PubMed
    Score: 0.178
  11. Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer. Clin Cancer Res. 1998 May; 4(5):1193-201.
    View in: PubMed
    Score: 0.158
  12. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemother Pharmacol. 2017 Sep; 80(3):583-589.
    View in: PubMed
    Score: 0.149
  13. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 2016 Dec 27; 7(52):86280-86289.
    View in: PubMed
    Score: 0.144
  14. Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer. Urol Oncol. 1996 Nov-Dec; 2(6):191-7.
    View in: PubMed
    Score: 0.142
  15. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer. 2016 06 15; 122(12):1836-43.
    View in: PubMed
    Score: 0.136
  16. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol. 1995 Nov; 154(5):1719-22.
    View in: PubMed
    Score: 0.133
  17. Management of Clinical Stage I Testicular Cancer: How Should We Define Success? J Clin Oncol. 2015 Jul 10; 33(20):2321-2.
    View in: PubMed
    Score: 0.129
  18. Variant prostate carcinoma and elevated serum CA-125. Can J Urol. 2014 Oct; 21(5):7442-8.
    View in: PubMed
    Score: 0.123
  19. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer. 2015 Jan 01; 121(1):69-76.
    View in: PubMed
    Score: 0.122
  20. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol. 2015 Jan; 67(1):53-60.
    View in: PubMed
    Score: 0.120
  21. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013 Jul 01; 19(13):3621-30.
    View in: PubMed
    Score: 0.112
  22. Effect of Paget's disease of bone (osteitis deformans) on the progression of prostate cancer bone metastasis. Br J Cancer. 2012 Aug 07; 107(4):646-51.
    View in: PubMed
    Score: 0.106
  23. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res. 2008 Jun 15; 14(12):3729-36.
    View in: PubMed
    Score: 0.080
  24. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene. 2008 Sep 04; 27(39):5195-203.
    View in: PubMed
    Score: 0.079
  25. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res. 2007 Oct 01; 13(19):5816-24.
    View in: PubMed
    Score: 0.076
  26. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004 Jun 01; 22(11):2108-21.
    View in: PubMed
    Score: 0.060
  27. A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer. 2003 Jun 15; 97(12):2988-94.
    View in: PubMed
    Score: 0.056
  28. Targeting prostate cancer bone metastases. Cancer. 2003 Feb 01; 97(3 Suppl):785-8.
    View in: PubMed
    Score: 0.055
  29. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer. 2003 Feb 01; 97(3):561-7.
    View in: PubMed
    Score: 0.055
  30. Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study. Urol Oncol. 2003 Jan-Feb; 21(1):21-6.
    View in: PubMed
    Score: 0.055
  31. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 2002 Jul 15; 20(14):3072-80.
    View in: PubMed
    Score: 0.053
  32. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol. 2002 Jul 01; 20(13):2965-70.
    View in: PubMed
    Score: 0.053
  33. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol. 2002 Mar 01; 20(5):1361-7.
    View in: PubMed
    Score: 0.051
  34. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-na?ve prostate cancer. Eur J Cancer. 2021 11; 157:259-267.
    View in: PubMed
    Score: 0.050
  35. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2021 02; 19(1):22-31.e5.
    View in: PubMed
    Score: 0.046
  36. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2020 03; 127:67-75.
    View in: PubMed
    Score: 0.044
  37. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol. 2019 10; 20(10):1432-1443.
    View in: PubMed
    Score: 0.043
  38. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2371-6.
    View in: PubMed
    Score: 0.038
  39. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2493-500.
    View in: PubMed
    Score: 0.038
  40. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer. 1997 Dec 01; 80(11):2128-32.
    View in: PubMed
    Score: 0.038
  41. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol. 1995 Sep; 13(9):2272-7.
    View in: PubMed
    Score: 0.033
  42. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials. Br J Cancer. 2012 Oct 23; 107(9):1547-53.
    View in: PubMed
    Score: 0.027
  43. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A. 2011 Nov 15; 108(46):18637-42.
    View in: PubMed
    Score: 0.025
  44. NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res. 2009 Mar 15; 15(6):2130-9.
    View in: PubMed
    Score: 0.021
  45. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer. 2002 May 20; 86(10):1555-60.
    View in: PubMed
    Score: 0.013
  46. A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer. 2000 Aug 01; 89(3):615-8.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.